Understanding SS-31 / Elamipretide
SS-31, also known as elamipretide, is a mitochondria-targeting peptide. The reference separates its Forzinity Barth syndrome context from broader anti-aging research and emphasizes that an approved narrow indication does not validate research-vial products or lower-dose longevity regimens.
SS-31 / Elamipretide
Mitochondria-targeting peptide
Mitochondrial and muscle-function research
Clinical and trial research
Broad longevity benefit has not been established.
Important Evidence Note
The approved Forzinity indication is specific to Barth syndrome and does not establish SS-31 as a general anti-aging or longevity treatment. Research-vial products and community regimens should not be assumed to be equivalent to the approved formulation.
SS-31 / Elamipretide Reported Dose Patterns
The reference distinguishes the approved Forzinity context from the TAZPOWER trial program. These contexts should not be interpreted as a universal personal dosing protocol.
SC example
Per administration
Frequency
Daily total
Reported cycle
Forzinity Context
40 mg SC daily
Daily
40 mg/day
Product-specific clinical use
40 mg SC daily
20 mg daily
Daily
20 mg/day
Product-specific clinical use
TAZPOWER Trial
Trial-specific dosing
Daily
Not applicable; trial-specific
12-week crossover periods with 4-week washout; extension up to 168 weeks
Per administration
40 mg SC daily
Reported cycle
Product-specific clinical use
Per administration
20 mg daily
Reported cycle
Product-specific clinical use
Per administration
Trial-specific dosing
Daily total
Not applicable; trial-specific
Reported cycle
12-week crossover periods with 4-week washout; extension up to 168 weeks
The Forzinity dosing context applies to the approved product and indication. Dialysis dosing was not defined in the source, and use below 30 kg was not approved. These details should not be converted into a generic research-vial regimen.
Indication-Specific Clinical Context
The Forzinity dosing context applies to the approved product and indication. Dialysis dosing was not defined in the source, and use below 30 kg was not approved. These details should not be converted into a generic research-vial regimen.
SS-31 / Elamipretide Safety Considerations
The reference reports injection-site reactions as common and notes hypersensitivity and benzyl-alcohol cautions. Renal adjustment is product-specific.
SS-31 / Elamipretide Storage and Product Handling
Forzinity Solution
Follow the specific finished-product label and storage instructions.
Reconstituted Research Powder
Research-powder handling and stability should not be assumed to match the Forzinity solution.
Formulation Difference
Forzinity solution and reconstituted research powder represent different product formats.
Product Verification
Verify the exact formulation and product-specific instructions before interpreting storage requirements.
SS-31 / Elamipretide Concentration Calculator
The reference provides independently recomputed mathematical concentration examples. These calculations are examples only and are not mixing or administration instructions.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
U means a U-100 volume marking: 1 U = 0.01 mL. These are mathematical examples only, not mixing or administration instructions.
SS-31 / Elamipretide Clinical Findings
SS-31 / elamipretide has been studied in mitochondrial and muscle-function contexts, including the TAZPOWER program. The reference emphasizes that randomized and uncontrolled findings should not be presented interchangeably.
Barth Syndrome Context
Forzinity has an approved narrow context for improving muscle strength in people with Barth syndrome meeting the specified weight criteria.
TAZPOWER Research
The short randomized crossover phase missed its co-primary endpoints, while the longer open-label extension reported improvements.
Evidence Limitation
Randomized trial findings and uncontrolled extension findings should not be presented as equivalent evidence for broad longevity or anti-aging benefits.
SS-31 / Elamipretide Regulatory Status
Narrow Approved Clinical Context
The reference identifies Forzinity / elamipretide as having an approved narrow Barth syndrome context. This approval does not establish SS-31 as a general anti-aging or longevity treatment, nor does it make research-vial products equivalent to the approved finished product.
Educational information only. Not medical advice, diagnosis, or treatment guidance. Product formulation, indication, route, concentration, and regulatory status should always be interpreted from the applicable official product information.
